Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Primary result · Major kidney disease eventsResult — go to the resultHazard ratio 0.76 95% CI 0.66–0.88Authors' conclusion
Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease.
Study context
- Population
- Patients with T2D and CKD (eGFR 50 to 75 ml/min/1.73 m² and urinary albumin-to-creatinine ratio >300 and <5000, or eGFR 25 to <50 ml/min/1.73 m² and urinary albumin-to-creatinine ratio >100 and <5000)randomized
- Participants
- 3,533 patients
- Comparison
- Subcutaneous semaglutide 1.0 mg weekly vs placebo
- Semaglutiden = 1,767
- Placebon = 1,766reference
- Primary endpoint
- Major kidney disease events: composite of kidney failure onset (dialysis, transplantation or eGFR <15 ml/min/1.73 m²), ≥50% eGFR reduction from baseline, or death from kidney-related or cardiovascular causes
- Follow-up
- Median 3.4 years
Methodological detailsplacebo-controlled, prespecified interim analysis, Early trial cessation recommended at a prespecified interim analysis
- Placebo-controlled
- Prespecified interim analysis
- Early trial cessation recommended at a prespecified interim analysis
Primary result
Major kidney disease events
Hazard ratio
0.76
95% CI 0.66–0.88
P = 0.0003
Events by treatment group
Semaglutide
331
events
Placebo
410
events
Semaglutidevs Placebo
HR 0.76 (95% CI 0.66–0.88); P = 0.0003
As reported in the abstract
Secondary outcomes
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| Composite of kidney-specific components of the primary outcome | 0.79 (0.66–0.94) | ||
| Death from cardiovascular causes | 0.71 (0.56–0.89) | ||
| Major cardiovascular events (confirmatory secondary)18% lower risk with semaglutide · tested hierarchically | 0.82 (0.68–0.98) | P = 0.029 | |
| Death from any cause (confirmatory secondary)20% lower risk with semaglutide · tested hierarchically | 0.80 (0.67–0.95) | P = 0.01 | |
| 0.512Hazard ratio (log scale) |
| Outcome | Difference (ml per minute per 1.73 m²) | P value |
|---|---|---|
| Mean annual eGFR slope (confirmatory secondary)Less steep (slower decrease) with semaglutide · tested hierarchically | 1.16 | P < 0.001 |
Safety
Serious adverse events
Original publication
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. Published 24 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →